Trial Search Results

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerabiilty and efficacy (Extension Part).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Novartis Pharmaceuticals


  • Drug: BAF312
  • Drug: Placebo


Phase 3


Inclusion Criteria:

   - Prior history of relapsing remitting MS

   - SPMS defined as progressive increase of disability over at least 6 months

   - EDSS score of 3.0 to 6.5

   - No relapse of corticosteroid treatment within 3 months

Exclusion Criteria:

   - Women of child bearing potential must use reliable forms of contraception.

   - Diagnosis of Macular edema during screening period

   - Any medically unstable condition determined by investigator.

   - Unable to undergo MRI scans

   - Hypersensitivity to any study drugs or drugs of similar class Other protocol defined
   inclusion/exclusion may apply.

Ages Eligible for Study

18 Years - 60 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Angela Campbell